Shares of CareDx, Inc (NASDAQ:CDNA – Get Rating) reached a new 52-week low during mid-day trading on Tuesday . The company traded as low as $11.97 and last traded at $11.97, with a volume of 3383 shares trading hands. The stock had previously closed at $12.46.
Analysts Set New Price Targets
A number of equities analysts have issued reports on CDNA shares. Raymond James decreased their price objective on shares of CareDx from $35.00 to $26.00 and set a “strong-buy” rating on the stock in a research report on Monday, November 7th. The Goldman Sachs Group decreased their price objective on shares of CareDx from $45.00 to $40.00 and set a “buy” rating on the stock in a research report on Friday, November 4th. StockNews.com upgraded shares of CareDx from a “sell” rating to a “hold” rating in a research report on Friday, November 4th. Finally, BTIG Research decreased their price objective on shares of CareDx from $37.00 to $28.00 and set a “buy” rating on the stock in a research report on Monday, November 7th. One research analyst has rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $46.20.
CareDx Trading Up 2.3 %
The business’s 50 day moving average price is $16.62 and its two-hundred day moving average price is $20.71. The stock has a market cap of $680.46 million, a P/E ratio of -9.01 and a beta of 1.03.
Institutional Investors Weigh In On CareDx
CareDx Company Profile
CareDx, Inc discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.
- Get a free copy of the StockNews.com research report on CareDx (CDNA)
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
- Microsoft Shares: Is it Time to Back Up the Truck?
- Institutional Support for Analog Devices Remains High
- Three CBD Stocks to Dominate a Budding Industry
- Is the 60/40 Portfolio Mix Still in Vogue?
Receive News & Ratings for CareDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx and related companies with MarketBeat.com's FREE daily email newsletter.